Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors
Not Applicable
- Conditions
- Advanced/recurrent breast cancer
- Registration Number
- JPRN-UMIN000004345
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active double cancer 2. Patients with life-threatening symptoms, extensive organ metastasis (1/3 of the organ), or brain metastasis 3. Patients with a past history of severe drug hypersensitivity 4. Pregnant or breastfeeding females 5. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method